{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "BAX", "name": "Baxter International Inc.", "url": "https://frontierpicks.com/dossiers/BAX/", "json_url": "https://frontierpicks.com/dossiers/BAX.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a4", "n": 4 }, "current_thesis": "Baxter International's turnaround re-rating failed its published $24 weekly-close test when the shares closed at $23.80 on 2026-09-11. The operating-recovery premise remains unconfirmed by repeatable earnings improvement.", "invalidation_trigger": "A weekly close below $24 invalidates the July guidance-led re-rating; the 2026-09-11 adjusted close of $23.80 has already met that condition. A subsequent reduction of FY26 adjusted diluted EPS guidance below $1.95 would also undermine the operating premise.", "catalyst_date": "2026-10-01", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "FY26 guidance of $1.95-$2.15 adjusted diluted EPS is stated for continuing operations; reported sales growth (3-4%) is guided above organic (2-3%).", "An FDA Class I classification dated 2026-08-13 covers removal of certain Duo-Vent solution set lots; Baxter reported no serious injuries or deaths.", "The CFO seat changes hands 2026-10-01 (John Rogers), so the Q3 print would be the first quarter presented by an incoming finance chief.", "No published theme cluster carries this name; it trades as a single-name situation without a sector narrative behind it." ], "body_markdown": "## Current Thesis\n\nBaxter International's turnaround re-rating has failed its published price test: the 2026-09-11 weekly close of $23.80 breached the $24 invalidation level established in the September 5 research. The operating premise was the July 30 increase in full-year 2026 organic sales-growth guidance to 2–3% and adjusted diluted earnings per share (EPS) guidance to $1.95–$2.15. Baxter reiterated that outlook on August 19. [Baxter's July 30 results](https://investor.baxter.com/investors/events-and-news/news/press-release-details/2026/Baxter-Reports-Second-Quarter-2026-Results/default.aspx); [August 19 disclosure](https://www.sec.gov/Archives/edgar/data/10456/000119312526356188/d154782dex991.htm).\n\nFor that guidance-led re-rating, the narrative is dead — the September 11 weekly close crossed the previously published thesis-break threshold. That is an interpretation of the measured price breach; it does not establish that operating guidance has failed. The original case has reached its invalidated outcome.\n\n## Bull Case\n\n- **Sales growth remains documented.** Baxter reported second-quarter 2026 sales of $2.96 billion, up 5% both organically and as reported, on July 30. This supports the operating-recovery premise, although it does not establish a durable earnings trend. [July 30 results](https://investor.baxter.com/investors/events-and-news/news/press-release-details/2026/Baxter-Reports-Second-Quarter-2026-Results/default.aspx).\n- **Management identified an inventory improvement.** At the September 9 Wells Fargo conference, chief executive Andrew Hider said higher-cost inventory had sold through and identified at least $50 million of second-quarter impact. His expectation of sequential relief is testable: a failure of that inventory burden to ease in the third quarter would contradict it. [September 9 conference transcript](https://uk.investing.com/news/stock-market-news/baxter-at-wells-fargo-conference-growth-improves-as-turnaround-continues-93CH-4863071).\n\n## Bear Case\n\n- **Price invalidation has already occurred.** The supplied adjusted market series records a September 11 close of $23.80, below the September 5 research threshold of $24 on a weekly close. The threshold remains unchanged in this refresh.\n- **Earnings have not matched sales.** July 30 results showed second-quarter adjusted diluted EPS of $0.56, down 5% year over year despite sales growth. That divergence leaves repeatable earnings improvement unestablished. [July 30 results](https://investor.baxter.com/investors/events-and-news/news/press-release-details/2026/Baxter-Reports-Second-Quarter-2026-Results/default.aspx).\n- **Temporary benefits complicate the outlook.** On September 9, management described the tariff refund as nonrecurring and declined to provide 2027 guidance. Kevin Moran, vice president of investor relations, identified the expiration of transition service agreements as a future earnings headwind; subsequent guidance showing no adverse contribution from their expiration would contradict that expectation. [September 9 conference transcript](https://uk.investing.com/news/stock-market-news/baxter-at-wells-fargo-conference-growth-improves-as-turnaround-continues-93CH-4863071).\n\n## Setup & Price Structure\n\nThe September 11 adjusted close was $23.80, with the supplied series showing a three-month price increase of 14.1% and a 14-period relative strength index (RSI) of 22.7. The same snapshot places the shares 16.0% below the recorded 52-week high of $28.34. A positive three-month change therefore coexists with a breach of the published weekly-close condition.\n\nThe supplied July 31 theFly/TipRanks summaries documented clustered analyst target increases from Deutsche Bank, Bank of America and TD Cowen. That is an observable coverage cluster, not a measurement of investor exposure. No current fund-flow, short-interest, retail-participation or moving-average measurements are supplied; crowding and the distance above a rising average cannot be established.\n\nThe September 9 conference preceded the September 11 close, but that sequence alone does not establish what caused the decline. The available observations are too limited to support a causal claim.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-10-01 — Finance leadership changes.** John Rogers becomes chief financial officer, as announced on August 19. The appointment disclosure also reiterated the July outlook; it did not schedule an October 1 earnings update. A change of officeholder alone cannot confirm recurring earnings improvement. [August 19 disclosure](https://www.sec.gov/Archives/edgar/data/10456/000119312526356188/d154782dex991.htm).\n\nAs of September 13, the next quarterly-results date remains unconfirmed in the available evidence. The earlier late-October estimate is not treated as a company-announced event.\n\n## What Would Change Our Mind\n\nThe loss of the published $24 threshold settles the original price case: a weekly close below $24 was its invalidation condition, and the September 11 close of $23.80 satisfied it. A subsequent recovery above that level would not erase the recorded breach.\n\nA separate operating-recovery case would require quarterly evidence of repeatable earnings improvement. The concrete test arising from Hider's September 9 remarks is whether the third-quarter inventory burden eases sequentially; failure to ease would reject that proposed source of improvement. A reduction of the July 30 full-year adjusted diluted EPS guidance below its $1.95 lower bound would separately undermine the guidance-led recovery premise.\n\n## Correlation Notes\n\nThis remains a single-company turnaround assessment. The September 11 snapshot supplies Baxter's three-month price change of 14.1%, but no matching sector or peer return series; it cannot establish correlation or sector-relative strength. Neither a common industry label nor the July 31 analyst-coverage cluster demonstrates that a group move explains the shares' behavior.", "first_seen": "2026-09-04", "last_analyzed": "2026-09-20T08:07:04+00:00", "last_synthesized": "2026-09-13", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }